TerrAscend earnings release, August 6, 2026

TerrAscend Corp. (TSNDF) · Form 8-K, Item 2.02 · Filed · SEC filing

TerrAscend Reports Second Quarter 2026 Financial Results

Q2 2026 Net Revenue of $67.1 Million, Up Sequentially and Year-Over-Year

Q2 2026 Gross Profit Margin of 54.0%, Up 120 Basis Points Sequentially and 290 Basis Points Year-Over-Year

Q2 2026 Net Cash Provided from Continuing Operations of $7.4 Million, Representing 12.5% Operating Cash Flow Yield¹

Q2 2026 Free Cash Flow¹ of $5.7 Million, Representing 9.9% Free Cash Flow Yield¹

16th Consecutive Quarter of Positive Cash Flow from Continuing Operations and 12th Consecutive Quarter of Positive Free Cash Flow¹

Completed an Oversubscribed $21.8 Million Convertible Debt Financing, Extending Convertible Debt Maturity to 2031 and Enhancing Financial Flexibility

TORONTO, August 6, 2026 - TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today reported its financial results for the second quarter ended June 30, 2026. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise.

The following financial measures are reported as results from continuing operations unless otherwise noted, due to the Company’s previously stated intention to sell all of its Michigan assets, which are reported as discontinued operations effective as of the second quarter ended June 30, 2025. All historical periods have been restated accordingly.

Second Quarter 2026 Financial Highlights

• Net Revenue of $67.1 million, compared to $65.5 million in the first quarter of 2026 and $65.0 million in the second quarter of 2025

• Gross Profit Margin of 54.0%, compared to 52.8% in the first quarter of 2026 and 51.1% in the second quarter of 2025

• GAAP Net Loss from continuing operations was $10.1 million, compared to $6.8 million in the first quarter of 2026 and $6.4 million in the second quarter of 2025

• Adjusted EBITDA from continuing operations¹ was $17.7 million or 26.3% of net revenue, compared to $17.4 million or 26.5% of net revenue in the first quarter of 2026 and $16.0 million or 24.6% of net revenue in the second quarter of 2025. Q2 Adjusted EBITDA represents 11% year-on-year growth.

• Net Cash provided from continuing operations was $7.4 million

• Free Cash Flow¹ was $5.7 million

“Our second quarter net revenue, gross margin and Adjusted EBITDA increased sequentially and year-over-year, exceeding our expectations. We also generated another quarter of positive operating and free cash flow, ending the quarter with a strong cash position of $42.0 million,” said Jason Wild, Executive Chairman of TerrAscend. “Revenue increased sequentially across New Jersey, Maryland and Pennsylvania, with strength in both our retail and wholesale channels. These results demonstrate the consistency of our execution and operational efficiency, as well as the quality and the strength of our brands across our core markets.”

Mr. Wild added, “During the quarter, we strengthened our balance sheet through an oversubscribed convertible debenture financing that extended our convertible debt maturities to 2031 at a lower interest rate, and we signed an agreement to acquire our fifth dispensary in New Jersey. These actions enhance our financial flexibility and reinforce our disciplined approach to capital allocation and strategic growth. As regulatory momentum continues to build, we are taking the appropriate steps to prepare for an uplisting to a major U.S. exchange.”

Financial Summary Q2 2026 and Comparative Periods

Second Quarter 2026 Business and Operational Highlights

• Scheduled a Special Meeting of Shareholders for August 24, 2026 to vote on a proposed share consolidation, a key step toward listing on a major U.S. exchange.

• Appointed Eric Jackson as Chief Financial Officer, bringing more than two decades of finance and operational leadership across retail, consumer, and manufacturing sectors.

• Completed an oversubscribed convertible debenture financing for aggregate gross proceeds of $21.8 million, utilizing $11.1 million to retire existing higher-interest-rate senior unsecured convertible debentures, extending the vast majority of convertible debenture maturity to 2031, with the remainder of the capital available for mergers and acquisitions.

• Paid down $10.0 million on the principal of the Company’s term loan, which brings year-to-date term loan repayments to $15.5 million.

• Signed an agreement for the option to acquire ownership in Aunt Mary's, a high-performing dispensary in Flemington, New Jersey, which generates over $10.0 million in annualized revenue and is expected to be immediately accretive on an EBITDA and free cash flow basis. Aunt Mary’s would be the Company’s fifth dispensary in the state.

• In New Jersey, all three Apothecarium stores ranked within the top 25 in the state, with two improving in rank quarter-over-quarter, led by Phillipsburg at number 3².

• In Maryland, two of the four Apothecarium stores, Cumberland and Salisbury, ranked among the top 10 in the state².

• Improved to the number 4 position in Maryland at 6.0% market share, supported by the launch of Tyson 2.0 products as well as growth in vapes, prerolls, and edibles³.

• In Pennsylvania, five of the six Apothecarium stores ranked among the top 15 in the state, reflecting continued strength in retail productivity².

Subsequent Events

• Appointed Ziad Ghanem, President and Chief Executive Officer of TerrAscend, to the Board of Directors.

Financial statements

Income Statement

Financial Summary Q2 2026 and Comparative Periods (in millions)

Q2 2026Q1 2026Q2 2025
Revenue, net67.165.565
Quarter-over-Quarter increase2.4%
Year-over-Year increase3.3%
Gross profit36.334.633.2
Gross profit margin54.0%52.851.1
General & Administrative expenses22.921.521
Share-based compensation expense (included in G&A expenses above)0.80.90.8
G&A as a % of revenue, net34.0%32.832.3
Net loss from continuing operations-10.1-6.8-6.4
EBITDA from continuing operations114.817.315.9
Adjusted EBITDA from continuing operations117.717.416
Adjusted EBITDA Margin from continuing operations126.3%26.524.6
Net cash provided by operations - continuing operations7.48.77.3
Free Cash Flow15.77.85

Income Statement

For the Three Months Ended — (Amounts expressed in thousands of United States dollars, except for share and per share amounts)

For the Three Months Ended – June 30, 2026For the Three Months Ended – June 30, 2025For the Six Months Ended – June 30, 2026For the Six Months Ended – June 30, 2025
Revenue, net67,11965,006132,658129,309
Cost of sales30,86931,77161,80661,393
Gross profit36,25033,23570,85267,916
Operating expenses:General and administrative22,85220,98044,34942,129
Operating expenses:Amortization and depreciation1,2851,2842,8332,573
Operating expenses:Other operating expense36
Operating expenses:Total operating expenses24,13722,26447,21844,702
Operating expenses:Income from operations12,11310,97123,63423,214
Other expense (income)Finance and other expenses8,8108,74718,13517,082
Other expense (income)Unrealized and realized loss (gain) on investments271-7271735
Other expense (income)Loss (gain) on fair value of derivative liabilities1,171-279-232-376
Other expense (income)(Gain) loss from revaluation of contingent consideration-34346
Other expense (income)Unrealized and realized foreign exchange loss (gain)333-648511-607
Other expense (income)Income from continuing operations before provision for income taxes1,5283,1924,9496,034
Other expense (income)Provision for income taxes11,5879,59821,83720,105
Other expense (income)Net loss from continuing operations-10,059-6,406-16,888-14,071
Discontinued operations:Income (loss) from discontinued operations, net of tax2,004-41,701828-46,305
Discontinued operations:Net loss-8,055-48,107-16,060-60,376
Discontinued operations:Foreign currency translation adjustment-317854-619840
Discontinued operations:Comprehensive loss-7,738-48,961-15,441-61,216
Net loss from continuing operations attributable to:Common and proportionate Shareholders of the Company-11,165-7,684-19,050-16,651
Net loss from continuing operations attributable to:Non-controlling interests1,1061,2782,1622,580
Comprehensive loss attributable to:Common and proportionate Shareholders of the Company-8,844-50,239-17,603-63,796
Comprehensive loss attributable to:Non-controlling interests1,1061,2782,1622,580
Net (loss) income per share - basic & diluted:Continuing operations-0.04-0.03-0.06-0.06
Net (loss) income per share - basic & diluted:Discontinued operations0.01-0.14-0.16
Net (loss) income per share - basic & diluted:Net loss per share - basic & diluted-0.03-0.17-0.06-0.22
Net (loss) income per share - basic & diluted:Weighted average number of outstanding common shares - basic & diluted309,364,563299,087,022308,950,479296,137,440

Balance Sheet

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

At – June 30, 2026At – December 31, 2025
Current assetsCash and cash equivalents42,02637,414
Current assetsRestricted cash110
Current assetsAccounts receivable, net16,32316,898
Current assetsInvestments91362
Current assetsInventory39,17934,054
Current assetsPrepaid expenses and other current assets15,8448,557
Current assetsAssets from discontinued operations, current12,713
Current assetsTotal current assets113,463110,108
Non-current assetsProperty and equipment, net123,763129,932
Non-current assetsDeposits60
Non-current assetsOperating lease right of use assets26,51726,691
Non-current assetsIntangible assets, net175,337167,310
Non-current assetsGoodwill113,892109,770
Non-current assetsOther non-current assets73313,508
Non-current assetsTotal non-current assets440,242447,271
Non-current assetsTotal assets553,705557,379
Current liabilitiesAccounts payable and accrued liabilities40,13339,807
Current liabilitiesDeferred revenue4,4063,993
Current liabilitiesConvertible debt10,355
Current liabilitiesLoans payable14,0495,322
Current liabilitiesOperating lease liability1,1191,511
Current liabilitiesDerivative liability967
Current liabilitiesCorporate income tax payable2,2905,360
Current liabilitiesLiabilities from discontinued operations12,616
Current liabilitiesTotal current liabilities61,99779,931
Non-current liabilitiesLoans payable183,226203,846
Non-current liabilitiesOperating lease liability28,94828,555
Non-current liabilitiesDerivative liability14,6882,221
Non-current liabilitiesConvertible debt16,2716,896
Non-current liabilitiesDeferred income tax liability11,9008,025
Non-current liabilitiesLiability on uncertain tax position152,547128,798

Cash Flow

For the Six Months Ended — (Amounts expressed in thousands of United States dollars, except for share and per share amounts)

For the Six Months Ended – June 30, 2026For the Six Months Ended – June 30, 2025
Operating activitiesNet loss from continuing operations-16,888-14,071
Adjustments to reconcile net loss to net cash provided by operating activitiesAccretion and accrued interest4,9464,306
Adjustments to reconcile net loss to net cash provided by operating activitiesDepreciation of property and equipment and amortization of intangible assets8,0217,729
Adjustments to reconcile net loss to net cash provided by operating activitiesAmortization of operating right-of-use assets730805
Adjustments to reconcile net loss to net cash provided by operating activitiesShare-based compensation1,7142,293
Adjustments to reconcile net loss to net cash provided by operating activitiesDeferred income tax expense484597
Adjustments to reconcile net loss to net cash provided by operating activitiesGain on fair value of derivative liabilities-232-376
Adjustments to reconcile net loss to net cash provided by operating activitiesUnrealized and realized loss on investments271735
Adjustments to reconcile net loss to net cash provided by operating activitiesLoss from revaluation of contingent consideration346
Adjustments to reconcile net loss to net cash provided by operating activitiesProvision for expected credit loss826673
Adjustments to reconcile net loss to net cash provided by operating activitiesUnrealized and realized foreign exchange loss (gain)511-607
Adjustments to reconcile net loss to net cash provided by operating activitiesImpairment and other36-5
Changes in operating assets and liabilitiesReceivables-262-511
Changes in operating assets and liabilitiesInventory-5,1284,580
Changes in operating assets and liabilitiesAccounts payable and accrued liabilities2,218-5,046
Changes in operating assets and liabilitiesIncome taxes paid and tax related liabilities20,43916,862
Changes in operating assets and liabilitiesPrepaid expense and other current assets-1,32279
Changes in operating assets and liabilitiesOther assets and liabilities-32790
Changes in operating assets and liabilitiesNet cash provided by operating activities - continuing operations16,03718,479
Changes in operating assets and liabilitiesNet cash used in operating activities - discontinued operations-971-7,658
Changes in operating assets and liabilitiesNet cash provided by operating activities15,06610,821
Investing activitiesInvestment in property and equipment-2,504-4,650
Investing activitiesInvestment in note receivable, net of interest received103123
Investing activitiesInvestment in intangible assets-44-726
Investing activitiesCash portion of consideration paid in acquisition, net of cash received-3,722-5,128
Investing activitiesRefund of deposit for business acquisition3,400
Investing activitiesDeposit for business acquisition-250
Investing activitiesNet cash used in investing activities - continuing operations-3,017-10,381
Investing activitiesNet cash provided by (used in) investing activities - discontinued operations1,293-737
Investing activitiesNet cash used in investing activities-1,724-11,118
Financing activitiesProceeds from loan payable, net of transaction costs5,000
Financing activitiesLoan principal paid, including exit fees-16,236-1,966
Financing activitiesCapital distributions paid to non-controlling interests-2,563-1,988
Financing activitiesPayment for contingent consideration-386
Financing activitiesProceeds from convertible debentures, net of issuance costs18,967
Financing activitiesConvertible debentures principal paid-8,630
Financing activitiesProceeds from exercise of stock options20
Financing activitiesRepurchases of common shares-391-377
Financing activitiesNet cash (used in) provided by financing activities - continuing operations-8,833283
Financing activitiesNet cash used in financing activities - discontinued operations-200
Financing activitiesNet cash (used in) provided by financing activities-9,033283
Financing activitiesNet increase (decrease) in cash and cash equivalents and restricted cash during the period4,309-14
Financing activitiesNet effects of foreign exchange193-191
Financing activitiesCash and cash equivalents and restricted cash, beginning of the period37,52426,987
Financing activitiesCash and cash equivalents and restricted cash, end of the period42,02626,782

Cash Flow

For the Three Months Ended — The table below reconciles Net cash provided by operating activities to Free Cash Flow:

For the Three Months Ended – June 30, 2026For the Three Months Ended – March 31, 2026For the Three Months Ended – June 30, 2025
Net cash provided by operating activities - continuing operations7,3858,6527,300
Capital expenditures for property and equipment-1,639-865-2,292
Free Cash Flow5,7467,7875,008
Full release

1. EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA margin from continuing operations, Free Cash Flow, and Free Cash Flow Yield are non-GAAP measures defined in the section titled “Definition and Reconciliation of Non-GAAP Measures” below and reconciled to the most directly comparable GAAP measure at the end of this release.... (truncated)by taking Net Cash Provided from Continuing Operations and Free Cash Flow on a trailing twelve-month basis and dividing by the market value of the Company’s outstanding and exchangeable shares as of June 30, 2026.

2. Source: LIT Alerts

3. Source: BDSA

Second Quarter 2026 Financial Results

Net revenue for the second quarter of 2026 was $67.1 million, compared to $65.5 million for the first quarter of 2026, and $65.0 million for the second quarter of 2025. The sequential and year-over-year improvement was driven by strength in retail and wholesale.

Gross profit margin from continuing operations for the second quarter of 2026 was 54.0%, as compared to 52.8% for the first quarter of 2026, and 51.1% for the second quarter of 2025. Sequential and year-over-year performance reflects continued strength across all markets.

G&A expenses for the second quarter of 2026 were $22.9 million and 34.0% of revenue, compared to $21.5 million and 32.8% of revenue for the first quarter of 2026, and $21.0 million and 32.3% of revenue for the second quarter of 2025.

GAAP net loss from continuing operations for the second quarter of 2026 was $10.1 million, compared to a net loss of $6.8 million for the first quarter of 2026, and a net loss of $6.4 million for the second quarter of 2025.

Adjusted EBITDA from continuing operations was $17.7 million for the second quarter of 2026, or 26.3% of revenue, compared to $17.4 million for first quarter of 2026, or 26.5% of revenue, and $16.0 million for the second quarter of 2025, or 24.6% of revenue.

Balance Sheet and Cash Flow

Cash and cash equivalents were

$42.0 million as of June 30, 2026. Net cash provided by continuing operations in the second quarter of 2026 was $7.4 million. This represents the Company’s sixteenth consecutive quarter of positive cash flow from continuing operations.

Capital expenditures were $1.6 million in the second quarter of 2026, primarily related to ongoing cultivation and facility optimization projects. Free cash flow was $5.7 million in the second quarter of 2026, representing the twelfth consecutive quarter of positive free cash flow.

As of June 30, 2026, there were approximately 383 million basic shares of the Company issued and outstanding, including 309 million common shares, 11 million preferred shares as converted, and 63 million exchangeable shares. Additionally, there were 23 million warrants outstanding at a weighted average price of $4.18 USD per share. During the six month period ending June 30, 2026, the Company completed the repurchase of 578,500 shares through its normal course issuer bid at a weighted average price of $0.67 USD per share.

Conference Call Details

TerrAscend will host a conference call today, Thursday, August 6, 2026, to discuss these results. Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Executive Officer, and Eric Jackson, Chief Financial Officer will host the call at 5:00 p.m. Eastern Time. A question-and-answer session will follow management's presentation.

About TerrAscend Corp.

TerrAscend Corp. is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. On April 23, 2026, the U.S. Department of Justice issued a final rule rescheduling marijuana contained in United States Food and Drug Administration (“FDA”)-approved drug products and marijuana subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act (“CSA”), which became effective on April 28, 2026. However, any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a Schedule I controlled substance under the CSA, and those who handle such material remain subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I controlled substances. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.

Forward-Looking Information and Forward-Looking Statements... (truncated) securities laws and “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forward-looking information are intended to be covered by the safe harbor provisions for forward-looking statements contained in those sections and the Private Securities Litigation Reform Act of 1995. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include, but are not limited to, the anticipated impact of cannabis-related regulatory developments, including the possibility that such regulatory developments may, over time, expand access to institutional capital and provide public multi-state operators like TerrAscend with a pathway toward a potential listing on the NASDAQ or NYSE; the Company's expectations regarding the status and timing of its listing applications with major U.S. stock exchanges; statements with respect to the Company’s expectations with respect to its business outlook, financial profile, and operational efficiencies; its market opportunities, growth prospects in new and existing markets, and M&A strategy; statements with respect to the occurrence, timing and expected outcomes resulting from the potential closing of the Aunt Mary’s dispensary transactions, including the timing and completion of the exercise of the option to acquire ownership in Aunt Mary’s, the expected financial contribution of the potential acquisition, including anticipated EBITDA and free cash flow accretion, TerrAscend’s ability to vertically integrate the dispensary and improve margins; and TerrAscend’s continued retail expansion strategy in New Jersey. Forward-looking information and forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information and forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking information and forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information and forward-looking statements are subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information and forward-looking statements. Such risks and uncertainties include, but are not limited to, whether the Company elects to make any share repurchases in connection with the normal course issuer bid, current and future market conditions; the Company’s ability to execute on its business strategy, drive efficiency, and achieve profitability and growth targets; the Company’s ability to continue generating positive cash flow from operations; the impact and scope of the rescheduling of cannabis, including the distinction between medical and adult-use cannabis and the ongoing nature of the broader rescheduling process; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and in the section titled “Risk Factors” in the Company’s Annual Report for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 12, 2026, as updated by its Quarterly Reports on Form 10-Q.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information or forward-looking statements, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

Definition and Reconciliation of Non-GAAP Measures

In addition to reporting the financial results in accordance with GAAP, the Company reports certain non-GAAP financial measures, including EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA margin from continuing operations, Free Cash Flow, and Free Cash Flow Yield. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) Free cash flow from net cash provided by operating activities from continuing operations less capital expenditures for property and equipment, which management believes is an important measurement of the Company's ability to generate additional cash from its business operations, (ii) Free Cash Flow Yield by taking Free cash flow on a trailing twelve-month basis and dividing by the market value of the Company’s outstanding and exchangeable shares, which management believes provides investors with important information regarding cash generation relative to the Company’s market valuation, and (iii) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted in each case to exclude provision for income taxes, finance expenses, and amortization and depreciation, and further adjusted for Adjusted EBITDA from continuing operations to exclude share-based compensation, loss (gain) on fair value of derivative liabilities, (gain) loss on lease termination, gain from revaluation of contingent consideration, unrealized and realized loss (gain) on investments, unrealized and realized foreign exchange loss (gain), and certain other one-time items, which management believes is not reflective of the ongoing operations and performance of the Company. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of each non-GAAP financial measure to the most directly comparable GAAP measure set forth below.

The Company believes EBITDA and Adjusted EBITDA from continuing operations are useful performance measures to assess the performance of the Company as it provides more meaningful ongoing operating results by excluding the effects of expenses that are not reflective of the Company’s underlying business performance and other one-time or non-recurring expenses.

For more information regarding the Company:

Eric Jackson

Chief Financial Officer

IR@terrascend.com

689-345-4114

Investor Relations Contact:

KCSA Strategic Communications

Valter Pinto, Managing Director

TerrAscend@KCSA.com

212-896-1254

TerrAscend Corp.

Consolidated Balance Sheets

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

TerrAscend Corp.

Consolidated Statements of Operations and Comprehensive Loss

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

TerrAscend Corp.

Consolidated Statements of Cash Flows

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

TerrAscend Corp.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

The table below reconciles net loss to EBITDA and Adjusted EBITDA:

The table below reconciles Net cash provided by operating activities to Free Cash Flow:

The table below reconciles Net cash provided by operating activities to Free Cash Flow Yield:

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.